OrthoPediatrics (NASDAQ:KIDS) Reaches New 12-Month High – Should You Buy?

Shares of OrthoPediatrics Corp. (NASDAQ:KIDS) reached a new 52-week high during trading on Wednesday. The stock traded as high as $33.03 and last traded at $32.9810, with a volume of 37,104 shares changing hands. The stock had previously closed at $30.43.

Analysts Set New Price Targets

KIDS has been the subject of a number of recent analyst reports. Lake Street Capital lifted their price objective on shares of OrthoPediatrics from $34.00 to $38.00 and gave the company a “buy” rating in a report on Wednesday, October 28th. Weiss Ratings reiterated a “sell (d-)” rating on shares of OrthoPediatrics in a research report on Tuesday. Truist Financial increased their target price on shares of OrthoPediatrics from $22.00 to $28.00 and gave the stock a “hold” rating in a research note on Wednesday, October 28th. BTIG Research raised their target price on OrthoPediatrics from $29.00 to $30.00 and gave the company a “buy” rating in a research report on Wednesday, October 28th. Finally, TD Cowen lifted their price target on OrthoPediatrics from $23.00 to $28.00 and gave the company a “buy” rating in a research note on Wednesday, October 28th. Seven analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, OrthoPediatrics has a consensus rating of “Moderate Buy” and a consensus target price of $30.75.

OrthoPediatrics Trading Up 6.9%

The company’s 50-day moving average price is $23.55 and its 200-day moving average price is $19.71. The firm has a market cap of $877.09 million, a price-to-earnings ratio of -23.57 and a beta of 0.90. The company has a quick ratio of 2.00, a current ratio of 4.55 and a debt-to-equity ratio of 0.29.

OrthoPediatrics (NASDAQ:KIDS) last released its earnings results on Tuesday, October 27th. The company reported ($0.23) EPS for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.02). OrthoPediatrics had a negative return on equity of 8.10% and a negative net margin of 12.83%. The company had revenue of $72.66 million for the quarter, compared to analysts’ expectations of $68.50 million. Equities analysts expect that OrthoPediatrics Corp. will post -1.09 EPS for the current fiscal year.

Insider Buying and Selling

In other news, Director David R. Pelizzon sold 302,369 shares of the firm’s stock in a transaction that occurred on Thursday, September 10th. The stock was sold at an average price of $21.01, for a total value of $6,352,772.69. Following the transaction, the director owned 6,201,764 shares in the company, valued at $130,299,061.64. This trade represents a 4.65% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, major shareholder Squadron Capital Llc sold 302,369 shares of OrthoPediatrics stock in a transaction that occurred on Thursday, September 10th. The stock was sold at an average price of $21.01, for a total value of $6,352,772.69. Following the completion of the sale, the insider directly owned 6,201,764 shares in the company, valued at $130,299,061.64. This represents a 4.65% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 2,100,000 shares of company stock worth $46,747,931. Insiders own 32.50% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in KIDS. GAMMA Investing LLC boosted its stake in OrthoPediatrics by 70.3% during the 3rd quarter. GAMMA Investing LLC now owns 1,165 shares of the company’s stock worth $26,000 after purchasing an additional 481 shares during the last quarter. Legal & General Group Plc purchased a new stake in shares of OrthoPediatrics during the second quarter worth $34,000. Quantinno Capital Management LP purchased a new stake in shares of OrthoPediatrics during the first quarter worth $160,000. Waverly Advisors LLC acquired a new stake in shares of OrthoPediatrics in the first quarter valued at about $184,000. Finally, R Squared Ltd acquired a new stake in shares of OrthoPediatrics in the first quarter valued at about $212,000. Hedge funds and other institutional investors own 69.05% of the company’s stock.

About OrthoPediatrics

OrthoPediatrics Corp. is a medical device company focused exclusively on developing and commercializing orthopedic products for children. The company designs implants, instruments and related technologies intended to address the distinct anatomical and clinical needs of pediatric patients, including those with congenital conditions, traumatic injuries and musculoskeletal disorders.

Its product portfolio covers pediatric trauma and deformity correction, scoliosis, limb reconstruction, sports medicine and other specialized orthopedic procedures.